CF PharmTech raises US$65mn to develop inhalation products, manufacturing capacity

CF PharmTech, Inc., a leading specialty pharmaceutical company that develops and manufactures inhalation products, has raised US$65 million in a Series D financing. Future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited led the financing along with other prestigious healthcare investment groups in China.

 
CF PharmTech, founded by seasoned industry experts and entrepreneurs with a successful track record in the US pharmaceutical industry, is focused on the development, manufacturing and commercialisation of high-quality inhalation products for the global market. Since its inception, CF PharmTech has established state-of-art research and manufacturing facilities to advance its product development. This new round of investment will not only expedite the submission of its product pipeline to meet regulatory approvals in China and abroad, but also expand its CDMO service to international clients.

Hai Lu, managing director of SDIC Fund Management, commented: "Drug delivery via pulmonary route bears significant technical challenges and it takes extraordinary effort to bring inhalation products to the market. CF PharmTech’s high caliber team has proved their ability to attract top industry talents to develop inhalation products for the global market. We are confident that they will achieve their business mission in the near future."

CF PharmTech, headquartered in Suzhou, China, develops metered dose inhaler, inhalation powder, nasal spray and blow-fill-seal products. It has established high-quality research and manufacturing environments to be compliant with US, EU and Chinese regulations.